FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis - Candlesense
EVFM Patents

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

-- Evofem now holds eleven Orange Book - listed patents covering SOLOSEC into late 2041 -- SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly-issued U.S. patent which covers SOLOSEC® (secnidazole) 2 g oral granules and one of its...

Related Questions

How will the extended patent protection for SOLOSEC affect Evofem's revenue projections and valuation? What is the expected market size and launch timeline for the SOLOSEC oral granules targeting BV and Trichomoniasis, and how does it compare to existing treatments? Will the new patent trigger any competitive responses or licensing disputes that could impact the stock price?
Find similar articles on Candlesense prnewswire